Jeff W Chou
Overview
Explore the profile of Jeff W Chou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1070
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berry L, Pullikuth A, Stearns K, Wang Y, Wagner C, Chou J, et al.
J Transl Med
. 2024 Nov;
22(1):1048.
PMID: 39568014
Background: While high-grade serous ovarian cancer (HGSC) has proven largely resistant to immunotherapy, sporadic incidents of partial and complete response have been observed in clinical trials and case reports. These...
2.
Deycmar S, Johnson B, Ray K, Schaaf G, Ryan D, Cullin C, et al.
J Transl Med
. 2024 Mar;
22(1):292.
PMID: 38504345
Background: Naturally occurring colorectal cancers (CRC) in rhesus macaques share many features with their human counterparts and are useful models for cancer immunotherapy; but mechanistic data are lacking regarding the...
3.
Raj S, Routh E, Chou J, Votanopoulos K, Triozzi P, Miller L
Cancer
. 2022 Jun;
128(17):3254-3264.
PMID: 35767280
Background: Cellular and intrinsic markers of sarcoma immunogenicity are poorly understood. To gain insight into whether tumor-immune interactions correlate with clinical aggressiveness, the authors examined the prognostic significance of immune...
4.
Anderson R, Miller L, Isom S, Chou J, Pladna K, Schramm N, et al.
Nat Commun
. 2022 Mar;
13(1):1673.
PMID: 35354808
Devimistat is a TCA cycle inhibitor. A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response...
5.
Pullikuth A, Routh E, Zimmerman K, Chifman J, Chou J, Soike M, et al.
Front Oncol
. 2021 Dec;
11:734959.
PMID: 34956864
Background: Triggering receptor expressed on myeloid cells (TREM)-1 is a key mediator of innate immunity previously associated with the severity of inflammatory disorders, and more recently, the inferior survival of...
6.
Skeletal muscle extracellular matrix remodeling with worsening glycemic control in nonhuman primates
Ruggiero A, Davis A, Sherrill C, Westwood B, Hawkins G, Palmer N, et al.
Am J Physiol Regul Integr Comp Physiol
. 2020 Nov;
320(3):R226-R235.
PMID: 33206559
Type 2 diabetes (T2D) development may be mediated by skeletal muscle (SkM) function, which is responsible for >80% of circulating glucose uptake. The goals of this study were to assess...
7.
Bayne R, Puckett S, Rodrigues L, Cramer S, Lee J, Furdui C, et al.
Mol Ther Oncolytics
. 2020 Jun;
17:496-507.
PMID: 32529027
A key principle of oncolytic viral therapy is that many cancers develop defects in their antiviral responses, making them more susceptible to virus infection. However, some cancers display resistance to...
8.
Ma L, Ainsworth H, Snipes J, Murea M, Choi Y, Langefeld C, et al.
Kidney Int Rep
. 2020 Jun;
5(6):891-904.
PMID: 32518871
Introduction: G1 and G2 nephropathy-risk variants cause mitochondrial dysfunction and contribute to kidney disease. Analyses were performed to determine the genetic regulation of and elucidate potential mechanisms in -nephropathy. Methods:...
9.
Wang Z, Zhao Q, Nie Y, Yu Y, Misra B, Zabalawi M, et al.
iScience
. 2020 May;
23(5):101125.
PMID: 32428862
Increased flux of glucose through glycolysis is a hallmark of inflammatory macrophages and is essential for optimal effector functions. Solute carrier (SLC) 37A2 is an endoplasmic reticulum-anchored phosphate-linked glucose-6-phosphate transporter...
10.
Gmeiner W, Miller L, Chou J, Dominijanni A, Mutkus L, Marini F, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32224870
Chemo-immunotherapy is central to the treatment of small cell lung cancer (SCLC). Despite modest progress made with the addition of immunotherapy, current cytotoxic regimens display minimal survival benefit and new...